Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements Clinical Trials

12 clinical trials for Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia — RECRUITING · PHASE2
• Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma — RECRUITING · PHASE2
• Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells — RECRUITING · PHASE2
• Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma — RECRUITING · PHASE1
• Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas — ACTIVE_NOT_RECRUITING · PHASE2
• TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma — WITHDRAWN · PHASE2
• huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia — TERMINATED · PHASE1
• Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma — WITHDRAWN · PHASE1
• Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas — COMPLETED · PHASE1

Refine this search